ОбзорГрафикПрофильОсновная статистикаФинансовые показателиНовости
Деривативы
TraderScreen

ARGENX SE EO -,10/  NL0010832176  /

gettex
15.11.2024  21:45:43 Изменение -27.800 Объем сделки Бид21:59:29 Предложение21:59:29 Рыночная капитализация Дивидендная доходность Коэффициент Цена/Доход
537.600EUR -4.92% 18
Оборот: 9,707.600		 535.000Величина цены спроса: 9 537.000Величина цены предложения: 9 32.12 млрдEUR - -
GlobeNewswire 28.08 argenx to Present at Upcoming Investor Conferences
GlobeNewswire 26.08 MDA Kicks Off Muscular Dystrophy Awareness Month in September with ‘30 Days of Strength’ Campaign wi...
GlobeNewswire 12.08 Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights
GlobeNewswire 25.07 argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
GlobeNewswire 18.07 argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 202...
GlobeNewswire 16.07 argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Ge...
GlobeNewswire 08.07 Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors
GlobeNewswire 25.06 argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 P...
GlobeNewswire 21.06 argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropat...
GlobeNewswire 17.06 argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcomi...
GlobeNewswire 13.06 Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
GlobeNewswire 04.06 argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewswire 09.05 argenx Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 07.05 argenx announces results of Annual General Meeting of Shareholders
GlobeNewswire 07.05 argenx to Present at BofA Securities 2024 Health Care Conference
GlobeNewswire 02.05 argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
GlobeNewswire 16.04 argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Pa...
GlobeNewswire 27.03 argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
GlobeNewswire 26.03 argenx Announces Annual General Meeting of Shareholders on May 7, 2024
GlobeNewswire 26.03 argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thr...
GlobeNewswire 07.03 argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of ...
GlobeNewswire 29.02 argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
GlobeNewswire 26.02 argenx to Present at Upcoming Investor Conferences
GlobeNewswire 22.02 argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29,...
GlobeNewswire 20.02 argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review f...